Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Instagram Outage Disrupts Thousands of U.S. Users 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Chinese pharmaceutical giant WuXi AppTec (SS:603259) expects its first-half net profit to more than double, driven by soaring demand for its contract research and manufacturing services. The company announced on Thursday that net profit attributable for the six months ending June 30 is projected to jump 101.9% year-over-year, reaching 8.56 billion yuan (approximately $1.19 billion). This surge includes a significant one-time gain from the partial divestment of its subsidiary, WuXi XDC Cayman.
Excluding one-off items, adjusted net profit is forecast to rise 44.4% to 6.31 billion yuan, underscoring strong performance in its integrated CRDMO (Contract Research, Development, and Manufacturing Organization) business model. The firm said that increasing global demand for end-to-end drug development solutions has been a key growth driver.
Total revenue for the first half of 2025 is expected to grow 20.6% year-over-year, reaching approximately 20.8 billion yuan. Revenue from core operations alone rose by 24.2%, reflecting enhanced operational efficiency and expanded manufacturing capacity.
WuXi AppTec’s continued investment in innovation, infrastructure, and client-centric services is positioning the company as a global leader in pharmaceutical outsourcing. With the biotech and pharmaceutical sectors increasingly relying on external partners to accelerate drug development pipelines, WuXi AppTec appears well-placed to capitalize on this structural shift.
The company’s impressive growth trajectory reinforces confidence in its CRDMO strategy, which offers integrated solutions across research, development, and manufacturing phases. As global demand for efficient and scalable pharmaceutical services rises, WuXi AppTec’s performance signals strong momentum heading into the second half of the year.
